Review
Aug 2026
Daratumumab in Antibody-Mediated Rejection After Kidney Transplantation: Mechanistic Rationale, Published Clinical Experience, and a Single-Center Case Series.
Daratumumab may serve as an adjunctive option for refractory AMR with persistent DSAs by targeting plasma cell-mediated alloantibody production by targeting CD38-expressing cells.
S. Sridhara, Elizabeth Cho, J. Nelson et al.
· Transplantation Proceedings · 0 citations